{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:01:07Z","timestamp":1790190067406,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cell-mediated immunity contributes to durable protection against COVID-19. mRNA-1283 vaccine, encoding the receptor-binding and N-terminal domains of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein, elicits higher neutralizing antibody responses than mRNA-1273, which encodes the full-length spike protein. We report T-cell responses following mRNA-1283 vaccination in preclinical and clinical studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For the preclinical evaluation, BALB\/c mice received a 2-dose primary series of mRNA-1273 (days 1 and 22), followed by 1 dose of mRNA-1283.222 or mRNA-1273.222 (ancestral + BA.4\/BA.5; day 63). C57BL\/6 mice received mRNA-1283.815 or mRNA-1273.815 (XBB.1.5; days 1 and 22). T-cell analyses were conducted on spleens from all vaccinated BALB\/c and C57BL mice (collected on days 77 and 36, respectively). In the clinical setting, a group of adult (\u226518 years) participants in a randomized phase 2 trial (NCT05137236) received 1 dose of mRNA-1283 (ancestral SARS-CoV-2), mRNA-1283.211 (ancestral + beta), mRNA-1283.529 (BA.1), or mRNA-1273 (ancestral), and their SARS-CoV-2 S-protein\u2013specific T-cell responses at days 1 (baseline), 29, 181, and 366 postvaccination were measured.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the mice studies, mRNA-1283 elicited potent S1-directed CD4+ and CD8+ T-cell responses. In the phase 2 study, mRNA-1283 increased S1-specific CD4+ and CD8+ Th1 responses at day 29 postvaccination compared with baseline; responses persisted through day 366 and were similar to mRNA-1273 for all tested strains (ancestral, beta, and BA.1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In preclinical and clinical studies, mRNA-1283 induced T-cell responses similar to mRNA-1273.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag248","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:45:19Z","timestamp":1779968719000},"page":"e522-e530","source":"Crossref","is-referenced-by-count":0,"title":["Cell-Mediated Immunity of mRNA-1283 Vaccine Encoding SARS-CoV-2 Spike Receptor-Binding and N-Terminal Domains in Preclinical and Clinical Studies"],"prefix":"10.1093","volume":"234","author":[{"given":"Alec W","family":"Freyn","sequence":"first","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadunanda","family":"Budigi","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Girard","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genesis","family":"Santos","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6728-910X","authenticated-orcid":false,"given":"Cathal","family":"Harmon","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Mahmudul","family":"Hasan","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9943-6080","authenticated-orcid":false,"given":"Shannon","family":"McGrath","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamuna D","family":"Paila","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carfi","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin","family":"Edwards","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahnuma","family":"Wahid","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituparna","family":"Das","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6254-1158","authenticated-orcid":false,"given":"Spyros","family":"Chalkias","sequence":"additional","affiliation":[{"name":"Moderna, Inc. , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"2026092314183969900_jiag248-B1","author":"World Health Organization"},{"key":"2026092314183969900_jiag248-B2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adf4100","article-title":"Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2","volume":"15","author":"Stewart-Jones","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026092314183969900_jiag248-B3","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"2026092314183969900_jiag248-B4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.chom.2021.03.005","article-title":"Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite","volume":"29","author":"Cerutti","year":"2021","journal-title":"Cell Host Microbe"},{"key":"2026092314183969900_jiag248-B5","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","article-title":"N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2","volume":"184","author":"McCallum","year":"2021","journal-title":"Cell"},{"key":"2026092314183969900_jiag248-B6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"2026092314183969900_jiag248-B7","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1016\/j.cell.2021.06.005","article-title":"SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2","volume":"184","author":"Amanat","year":"2021","journal-title":"Cell"},{"key":"2026092314183969900_jiag248-B8","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2026092314183969900_jiag248-B9","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S1473-3099(25)00236-1","article-title":"Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial","volume":"25","author":"Chalkias","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026092314183969900_jiag248-B10","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"2026092314183969900_jiag248-B11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"2026092314183969900_jiag248-B12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266852","article-title":"Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review","volume":"17","author":"Perry","year":"2022","journal-title":"PLoS One"},{"key":"2026092314183969900_jiag248-B13","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo1303","article-title":"Understanding T cell responses to COVID-19 is essential for informing public health strategies","volume":"7","author":"Vardhana","year":"2022","journal-title":"Sci Immunol"},{"key":"2026092314183969900_jiag248-B14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"2026092314183969900_jiag248-B15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000468","article-title":"T cell immune memory after covid-19 and vaccination","volume":"2","author":"Wang","year":"2023","journal-title":"BMJ Med"},{"key":"2026092314183969900_jiag248-B16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1505871","article-title":"mRNA-1273 COVID-19 vaccine induces CD4+ T-cell responses among solid organ transplant recipients","volume":"16","author":"Girard","year":"2025","journal-title":"Front Immunol"},{"key":"2026092314183969900_jiag248-B17","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1093\/infdis\/jiaf144","article-title":"Evaluation of cellular immune responses after mRNA-1273 vaccination in children 6 months to 11 years of age","volume":"231","author":"Rostad","year":"2025","journal-title":"J Infect Dis"},{"key":"2026092314183969900_jiag248-B18","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1410","article-title":"High-resolution analysis of individual spike peptide-specific CD4+ T-cell responses in vaccine recipients and COVID-19 patients","volume":"11","author":"Karsten","year":"2022","journal-title":"Clin Transl Immunol"},{"key":"2026092314183969900_jiag248-B19","article-title":"Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep Med"},{"key":"2026092314183969900_jiag248-B20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41541-026-01402-2","article-title":"Potent and dose-sparing next-generation SARS-CoV-2 vaccine, mRNA-1283, induces polyfunctional and durable T cell immunity","volume":"11","author":"Paila","year":"2026","journal-title":"NPJ Vaccines"},{"key":"2026092314183969900_jiag248-B21","doi-asserted-by":"crossref","first-page":"e754","DOI":"10.1093\/infdis\/jiaf022","article-title":"Safety and immunogenicity of SARS-CoV-2 spike receptor-binding domain and N-terminal domain mRNA vaccine","volume":"231","author":"Chalkias","year":"2025","journal-title":"J Infect Dis"},{"key":"2026092314183969900_jiag248-B22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2026092314183969900_jiag248-B23","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1128\/CVI.00342-08","article-title":"Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization","volume":"16","author":"Weinberg","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"2026092314183969900_jiag248-B24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri3158","article-title":"Standardizing immunophenotyping for the human immunology project","volume":"12","author":"Maecker","year":"2012","journal-title":"Nat Rev Immunol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag248\/68471438\/jiag248.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/3\/e522\/68471438\/jiag248.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/234\/3\/e522\/68471438\/jiag248.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:18:47Z","timestamp":1790187527000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/234\/3\/e522\/8701521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,4]]},"published-print":{"date-parts":[[2026,9,23]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag248","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,15]]},"published":{"date-parts":[[2026,6,4]]}}}